Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Overweight patients are susceptible to develop acute complications when they are admitted in
an Intensive Care Unit (ICU). Severe infection can be associated with cardiovascular failure
('shock") and is associated with 35-50% mortality. One of the key issue to cure infection is
to administer antibiotics. However, under dosing antibiotic is one of the main reason that
explain treatment failure. There are very few data concerning particularities of antibiotic
dosing in critically ill, overweight, patients. The aim of the present study is to describe
the pharmacokinetic of two main antibiotics (doripenem and piperacillin/Tazobactam) in both
overweight and non overweight critically ill patients presenting a septic shock. The
investigators hypothesis is that usual dose for those antibiotic may be accurate in non
overweight patients but is not in overweight patients.
Phase:
N/A
Details
Lead Sponsor:
University Hospital, Montpellier
Treatments:
Doripenem Penicillanic Acid Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam